ContraFect Announces Presentation of Data at ASM Microbe 2016

YONKERS, NY -- (Marketwired) -- 06/08/16 --

ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announces the presentation of data at the ASM Microbe 2016 Conference, to be held June 16-20, 2016 in Boston, MA.

The company will present preclinical findings on CF-301, which is currently in development for the treatment of Staphylococcus aureus (Staph aureus) bloodstream infections, including MRSA.

Late Breaker Poster Presentation:

Presentation Title: PK-PD Driver of Efficacy for CF-301, a Novel Anti-Staphylococcal Lysin: Implications for Human Target Dose
Session Day & Time: Saturday, June 18, 2016 12:45 PM - 2:45 PM ET
Poster Number: LB-053
Session Title: Session 150 - Saturday Late-Breaker Poster Presentations

Oral Presentations:

Presentation Title: Staphylococcus aureus Resistance to Lysin CF-301 Does Not Arise in Human Serum
Session Day & Time: Monday, June 20, 2016 3:45 PM - 4:00 PM ET
Location: Westin, Marina Ballroom II
Session Title: Session 437 - Staphylococcus aureus Infection Treatments: New Compounds, New Strategies

Presentation Title: Post-Antibiotic Effects of Lysin CF-301 Against Staphylococcus aureus
Session Day & Time: Monday, June 20, 2016 4:15 PM - 4:30 PM ET
Location: Westin, Marina Ballroom II
Session Title: Session 437 - Staphylococcus aureus Infection Treatments: New Compounds, New Strategies

ASM Microbe 2016 is the integration of two of the American Society of Microbiology's annual events: the General Meeting and ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy). Abstracts summarizing the data will be published on the ASM Microbe 2016 website:

About CF-301:

CF-301 is a recombinant bacteriophage-derived lysin with potent bactericidal activity against Staph aureus, a major cause of blood stream infections, or bacteremia. CF-301 has the potential to be a first-in-class treatment for Staph aureus bacteremia. It has a novel, rapid, and specific mechanism of bactericidal action against Staph aureus and does not impact the body's natural bacterial flora. By targeting a conserved region of the cell wall that is vital to bacteria, resistance is less likely to develop to CF-301. Combinations of CF-301 with standard of care antibiotics significantly increased bacterial killing and survival in animal models of disease when compared to treatment with antibiotics or CF-301 alone. In addition, in vitro and in vivo experiments have shown that CF-301 is highly active against biofilm infections. CF-301 was licensed from The Rockefeller University and is being developed at ContraFect.

About ContraFect:

ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (Methicillin-resistant Staph aureus) and influenza.


This press release contains, and our officers and representatives may make from time to time, "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar references to future periods. Examples of forward-looking statements include statements made regarding ContraFect's novel treatments for life-threatening, drug resistant infectious diseases, including protein therapeutics and antibody products and CF-301 preclinical findings. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including those detailed in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contact

Paul Boni
ContraFect Corporation
Tel: 914-207-2300

Source: ContraFect Corporation